Abstract
Background: Liver test monitoring is recommended every 3 months for the first year of therapy with elexacaftor/tezacaftor/ivacaftor (ETI) as there have been case reports of acute liver failure and hepatic necrosis following commencement of therapy. Abnormalities can present both patients and clinicians with difficult decisions. It is unclear why some people with cystic fibrosis (CF) develop liver test abnormalities.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
